Streetbeat News

Products Services

GOOG

MASI

Masimo has partnered with Google to develop a comprehensive smartwatch reference platform for OEMs using Wear OS. This platform will integrate Masimo's biosensing capabilities with Google's software expertise.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:49 am

NTRA

Natera's Signatera test shows significant predictive power for overall survival in colorectal cancer patients, according to new data from the GALAXY study presented at ESMO. The test indicates a nearly 10x advantage in survival at 36 months based on ctDNA status and a 50% reduction in death risk for Signatera-positive patients treated with ACT.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:46 am

MGNX

MacroGenics presented promising Phase 2 data for Vobra Duo in the TAMARACK study at ESMO 2024, showing encouraging antitumor activity. The company plans an investor call to discuss the results and provide a corporate update.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:31 am

ME

23andMe Therapeutics has released Phase 2 findings for its 23ME-00610 trial, showing clinical benefits in clear-cell renal-cell carcinoma. The study highlights the potential of CD200 and human genetics as biomarkers for patient selection.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:28 am

AAPL

DIS

NFLX

WBD

The 76th Primetime Emmy Awards highlighted the success of FX, a subsidiary of Disney, with 'Shōgun' and 'The Bear' winning multiple awards. Disney's FX led with 36 awards, surpassing its previous record. Netflix, HBO, and Apple TV+ also secured significant wins.

Portfolio Pulse from Ananya Gairola

September 16, 2024 | 7:24 am

EXEL

Exelixis, Inc. presented final Phase 3 CONTACT-02 study results at ESMO 2024, showing overall survival data for cabozantinib in combination with atezolizumab in metastatic prostate cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:19 am

LNTH

Lantheus presented positive Phase 3 SPLASH trial results for PSMA-positive metastatic prostate cancer at ESMO 2024. The study met its primary endpoint, showing significant improvement in radiographic progression-free survival and overall response rate. Patients also showed improved health-related quality of life.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:14 am

MXCT

MaxCyte, Inc. has entered a strategic platform license agreement with Kamau Therapeutics, allowing Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for gene correction therapies. MaxCyte will receive licensing fees and program-related revenue.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:08 am

GMAB

Genmab's Rinatabart Sesutecan (Rina-S) shows promising anti-tumor activity in heavily pretreated ovarian and endometrial cancer patients during a Phase 1/2 trial. A Phase 3 trial will further assess its safety and efficacy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:07 am

PEN

Penumbra, Inc. has secured CE Mark in Europe for its latest thrombectomy technologies, Lightning Flash 2.0 and Lightning Bolt 7, enhancing its position in the vascular treatment market.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:06 am